Aditxt

Aditxt Interest Expense

The Interest Expense of Aditxt (ADTX) as of Oct 21, 2026 is -6.95 M USD. In the previous year, Interest Expense was -6.38 M USD — a change of 8.90% (lower).

Interest Expense

-6.95 MUSD

YoY

8.90%

Last updated:

Interest Expense of Aditxt is 2024 -6.95 M USD. Interest Expense of Aditxt was 2023 -6.38 M USD. It decreases by 8.90% lower compared to the previous year.

The Aditxt Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
-80,000.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
-310,000.00 USD
Jan 1, 2021
-1.94 M USD
Jan 1, 2022
-2.23 M USD
Jan 1, 2023
-6.38 M USD
Jan 1, 2024
-6.95 M USD
The Aditxt Interest Expense history
YEARInterest ExpenseYoY
-6.95 MUSD+8.90%
-6.38 MUSD+186.09%
-2.23 MUSD+14.95%
-1.94 MUSD+525.81%
-310,000.00USD—
0.00USD-100.00%
-80,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aditxt Stock analysis

What does Aditxt do? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aditxt stock

Interest Expense of Aditxt is -6.95 M USD in 2024.

Interest Expense of Aditxt changed from -6.38 M USD to -6.95 M USD, representing a 8.90% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense Aditxt since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Aditxt historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Aditxt

All Key Metrics — Aditxt